Quantcast

Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:
Welcome, Guest. Please login or register.
July 23, 2014, 01:28:08 PM

Login with username, password and session length


Members
Stats
  • Total Posts: 631573
  • Total Topics: 47806
  • Online Today: 282
  • Online Ever: 585
  • (January 07, 2014, 02:31:47 PM)
Users Online

Welcome


Welcome to the POZ/AIDSmeds Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Fifty small breakthroughs in HIV science already in 2007 published part2  (Read 1716 times)

0 Members and 1 Guest are viewing this topic.

Offline bimazek

  • Member
  • Posts: 781
1000 new articles already pub 2007 on HIV   i just read thru all 1000 of these articles on hiv published in 2007
so i scanned them all, by the 3rd week in january 2007 there were only 87 articles with word hiv in them... these were the most intereting ones...here is what i found...

fifty small breakthroughs in HIV science....  i try to give a summary in non scientific words of each article    i have theory that no one is reading these articles... i mean the dr. and scientists there are just too many and a breakthrough might be missed by the right person   if you want to find the article just copy 3 or 4 unique words in article to google...

this could be a breakthrough to a new class of drugs..................
Why G3139 works poorly in cancer trials but might work well against HIV.
GE Parris - Med Hypotheses, 2007 - ncbi.nlm.nih.gov
Med Hypotheses. 2007 Mar 13; [Epub ahead of print], Click here to read Why G3139
works poorly in cancer trials but might work well against HIV. Parris GE. ...
Treatment interruption controversy continued..................
Treatment interruption in chronic HIV-1 infection: does it deliver?. Treatment interruption
CB Willberg, DF Nixon - Current Opinion in HIV & AIDS, 2007 - co-hivandaids.com
 Treatment interruption in chronic HIV-1 infection:
does it deliver?. Treatment interruption. Current Opinion in HIV & AIDS ...

antioxidants stop nerve damage by hiv
does this mean that antioxidants stop nerve damage by hiv...???
Preventing HIV-1 tat-induced neuronal apoptosis using antioxidant enzymes: Mechanistic and
L Agrawal, JP Louboutin, DS Strayer - Virology, 2007 - ncbi.nlm.nih.gov
Click here to read Preventing HIV-1 tat-induced neuronal apoptosis using
antioxidant enzymes: Mechanistic and therapeutic implications

Transfer of Autologous Gene-modified T Cells in HIV-infected Patients with Advanced Immunodeficiency
JV Lunzen, T Glaunsinger, I Stahmer, VV Baehr, C - Mol Ther, 2007 - ncbi.nlm.nih.gov
Click here to read Transfer of Autologous Gene-modified T Cells in HIV-infected
Patients with Advanced Immunodeficiency and Drug-resistant Virus. ...

HSCs resist hiv naturally they are a cell in human body... science will try to learn why soon...
An intrinsic host defense against HIV-1 integration? - PD Bieniasz - Journal of Clinical Investigation, 2007 - Am Soc Clin Investig... An intrinsic host defense against HIV-1 integration? ... HSCs are one of only a few cell
types that resist HIV-1 infection despite the presence of HIV-1 receptors. ...

some new drug candidates discovered...................
Discovery of small-molecule HIV-1 fusion and integrase inhibitors oleuropein and hydroxytyrosol: II.
S Lee-Huang, PL Huang, D Zhang, JW Lee, J Bao, Y - Biochem Biophys Res Commun, 2007 - ncbi.nlm.nih.gov
2007 Jan 22; [Epub ahead of print], Click here to read Discovery of small-molecule
HIV-1 fusion and integrase inhibitors oleuropein and hydroxytyrosol: II. ...

the selective pressures selective pressures are at it again...............
Cornering HIV: Taking advantage of interactions between selective pressures.
S Avila-Rios, G Reyes-Teran, E Espinosa - Med Hypotheses, 2007 - ncbi.nlm.nih.gov
Med Hypotheses. 2007 Feb 3; [Epub ahead of print], Click here to read Cornering
HIV: Taking advantage of interactions between selective pressures. ...
 

CTL-Based Vaccine Immunogen Selection
HIV-1 CTL-Based Vaccine Immunogen Selection: Antigen Diversity and Cellular Response Features -   2
F Li, H Horton, PB Gilbert, JM McElrath, L Corey, - Current HIV Research, 2007 - ingentaconnect.com
... HIV-1 CTL-Based Vaccine Immunogen Selection: Antigen Diversity and Cellular Response
Features ... a Statistical Center for HIV/AIDS Research and Prevention, ...
   
RNAi Therapy RNAi Therapy RNAi Therapy RNAi big future....
RNAi Therapy for HIV Infection: Principles and Practicalities -   4
Y Bennasser, ML Yeung, KT Jeang - BioDrugs, 2007 - biodrugs.adisonline.com
... RNAi Therapy for HIV Infection: Principles and Practicalities. ... 1. Inhibition of HIV
Replication in Tissue Culture Using Small Interfering RNA (siRNA) TOP.

cyclophilin A a possible drug class......???
Role of cyclophilin A in HIV replication -   3
J Votteler, V Wray, U Schubert - Future, 2007 - Future Medicine
... Cyclophilin A: an extensively investigated, but still enigmatic, cellular factor
in HIV-1 biology, ... Cyclophilin A regulates HIV-1 infectivity, ...

Long-Term Suppression of HIV Infection: Benefits and Limitations of Current Treatment Options -   2
MG Sension - Journal of Association of Nurses in AIDS Care, 2007 - Elsevier
... Feature. Long-Term Suppression of HIV Infection: Benefits and Limitations of Current
Treatment Options. Michael G. Sension MD 1 Available online 31 January 2007

Combined single-clade candidate HIV-1 vaccines induce T cell responses limited by multiple forms of
N Larke, EJ Im, R Wagner, C Williamson, AL - Eur J Immunol, 2007 - ncbi.nlm.nih.gov
Click here to read Combined single-clade candidate HIV-1 vaccines induce T cell
responses limited by multiple forms of in vivo immune interference

Selenium    beneficial  Selenium    beneficial  Selenium    beneficial  Selenium    beneficial 
Selenium appears beneficial in patients with HIV-1 infection
I Weekly - Inpharma Weekly, 2007 - inpharma.adisonline.com
... Selenium appears beneficial in patients with HIV-1 infection. [Clinical study].
Supplemental treatment with selenium may have benefit ..

Steric Gate hiv uses to Target Insertion
they found a  Steric Gate that hiv uses to Target Insertion of Unnatural Amino Acids
Investigating the" Steric Gate" of Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase -   3
GJ Klarmann, BM Eisenhauer, Y Zhang, M Gotte, JD - Biochemistry, 2007 - pubs.acs.org
... Investigating the "Steric Gate" of Human Immunodeficiency Virus Type 1 (HIV-1) Reverse
Transcriptase by Targeted Insertion of Unnatural Amino Acids. ...


even mexico researches have good days and breakthroughs... the pin them down strategy....
Cornering HIV: Taking advantage of interactions between selective pressures.    Center for Infectious Diseases Research, National Institute of Respiratory Diseases, Calzada de Tlalpan 4502, CP 14080 Mexico City, Mexico.
Adaptive immune responses, cellular restrictive factors and antiretroviral drugs, target multiple regions in the Human Immunodeficiency Virus (HIV) proteome, imposing diverse pressures to viral adaptation. However, the virus is remarkably able to escape from these pressures as mutations are selected. In many cases these mutants have diminished viral fitness. We propose that the concerted action of strategically placed agents and pressures in a host can limit HIV variation capacity while inhibiting its replication. These mechanisms would corner HIV by selecting conflicting adaptive mutations, each having a disadvantage in face of another selective pressure. This would keep the virus unable to efficiently escape the suppressive effects of selective pressures. Cornering between antiretroviral drugs and cytotoxic T lymphocytes may explain recent observations, and can be predicted and used in viral control strategies. This idea can be extended to numerous other identified sites in the viral genome that confer selective pressures. We describe these other sites and how they could be induced to interact in prophylactic or therapeutic cornering strategies, as well as their experimental verifications. Cornering would control HIV infection better than current strategies, focused on few, albeit important, sites in the HIV genome.
 
     
  a guy almost got HIV tested poz then didnt get it... near miss...   
 1: Sex Transm Dis. 2007 Feb 23;
 Spontaneous HIV-1 Seroreversion in An Adult Male.
 From the *HIV/GUM Directorate, Chelsea and Westminster Healthcare NHS Trust, London SW10 9NH, United Kingdom; daggerCentre for Infections, Health Protection Agency, London NW9 5HT United Kingdom; double daggerDepartment of Virology, Hammersmith Hospitals NHS Trust, London W12 0HS United Kingdom.
A man developed HIV-1 antibodies, which disappeared spontaneously. He had negative HIV viral load and p24 antigen tests and did not develop immunosuppression. Further investigations suggest the HIV-positive result was a nonspecific reaction. An alternative explanation is that he was exposed to HIV and had a "near-miss" HIV infection.
* Seroreversion in subjects receiving antiretroviral therapy during acute/early HIV infection. [Clin Infect Dis. 2006] PMID: 16447118
* Incomplete HIV type 1 antibody evolution and seroreversion in acutely infected individuals treated with early antiretroviral therapy. [Clin Infect Dis. 2005] PMID: 15736021
* Repeatedly positive human immunodeficiency virus type 1 DNA polymerase chain reaction in human immunodeficiency virus-exposed seroreverting infants. [Pediatr Infect Dis J. 1995] PMID: 8532421
* Measurement of HIV-1 p24 antigen by signal-amplification-boosted ELISA of heat-denatured plasma is a simple and inexpensive alternative to tests for viral RNA. [AIDS Rev. 2002] PMID: 12152521
* Antiretroviral treatment monitoring with an improved HIV-1 p24 antigen test: an inexpensive alternative to tests for viral RNA. [J Med Virol. 2001] PMID: 11536227
   

 


Terms of Membership for these forums
 

© 2014 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.